Johnson & Johnson Analyst Price Targets - Benzinga

Johnson & Johnson

JNJNYSE

Trade with Public

Trade with Public

$258.66

-6.08-2.3%

Últ. Act.: Oct 1, 7:45 PM

$259.25

-5.49-2.07%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Johnson & Johnson Analyst Price Targets - Benzinga

Johnson & Johnson Analyst Price Targets

Wall Street analyst price targets and consensus rating for Johnson & Johnson (JNJ).

Price Target Range — 8 Quarters

Analyst Consensus — 17 Analysts

11Buy

6Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$264Upside to Avg. PT+1.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$270→$285
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$290→$320
Sep 2, 2026	UBS	Michael Yee	PT Raise	Buy	$280→$320
Aug 6, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$270→$287
Aug 3, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$272→$282
Jul 17, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$270
Jul 16, 2026	Raymond James	Jayson Bedford	PT Raise	Outperform	$258→$265
Jul 16, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$287
Jul 16, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$263→$272
Jul 16, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$284→$294
Jul 13, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$250→$300
Jul 13, 2026	RBC Capital	Shagun Singh	PT Raise	Outperform	$265→$287
Jul 10, 2026	B of A Securities	Tim Anderson	PT Raise	Neutral	$254→$263
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$283→$284
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$285→$298
Jun 26, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$266→$270
May 13, 2026	Leerink Partners	David Risinger	Upgrade	Market Perform→Outperform	$265
Apr 15, 2026	Barclays	Matt Miksic	PT Raise	Equal-Weight	$234→$255
Apr 15, 2026	Stifel	Rick Wise	PT Raise	Hold	$220→$250
Apr 15, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$240→$263

More with Benzinga EdgeGet Access

Analyst Ratings News

Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss

Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.

Priya Nigam

PRO
JP Morgan Maintains Neutral on Johnson & Johnson, Raises Price Target to $285

JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target from $270 to $285.

Benzinga Newsdesk

PRO
HSBC Maintains Buy on Johnson & Johnson, Raises Price Target to $320

HSBC analyst Rajesh Kumar maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $290 to $320.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Johnson & Johnson, Raises Price Target to $320

UBS analyst Michael Yee maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $280 to $320.

Benzinga Newsdesk

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh

PRO
Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287

Guggenheim analyst Vamil Divan maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $270 to $287.

Benzinga Newsdesk